Article Text

Download PDFPDF
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
  1. H. T. See*,
  2. R. S. Freedman,
  3. A. P. Kudelka*,
  4. T. W. Burke,
  5. D. M. Gershenson,
  6. S. Tangjitgamol* and
  7. J. J. Kavanagh*
  1. * Department of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas
  2. Department of Gynecological Oncology, M.D. Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: John J. Kavanagh, MD, Department of Gynecologic Medical Oncology and Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 401, Houston, TX 77030-4009, USA. Email: jkavanag{at}


The objective of the analysis was to determine the effectiveness of re-treating patients with ovarian cancer, primary peritoneal cancer, and fallopian tube cancer with carboplatin after being deemed platinum resistant. From a database period January 1, 1996, to December 12, 2002, 34 patients were identified who received nonplatinum agents before resuming treatment with carboplatin. The median age was 65 years, and a median of two nonplatinum chemotherapy (range 1–5) prior to re-treatment with carboplatin was received. The median platinum-free interval from the time platinum was last received to re-treatment with carboplatin was 15.2 months (95% confidence interval [CI] 12.6–17.9; range 6.2–47.0). A median number of four cycles of carboplatin (range 1–11) was received. Two patients (5.9%) achieved partial response, while 21 patients (61.7%) achieved stable disease. The median time to progression for these 23 patients after re-treatment with carboplatin was 5.7 months (95% CI 5.2–6.3; range 1.8–15.3). Twenty-seven patients have died, and all patients have progressed. Seven patients are still receiving salvage therapy. The median overall survival from the time deemed to be platinum resistant is 23.2 months (95% CI 20.1–26.4). Patients who have been deemed platinum resistant may still benefit from platinum re-treatment after an interval of treatment with nonplatinum agents

  • carboplatin
  • ovarian cancer
  • platinum resistance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.